SCM
DNTH icon

Sterling Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Sterling Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2K Sell
166
-939
-85% -$82K ﹤0.01% 1980
2026
Q1 		$92.7K Sell
1,105
-192
-15% -$11.1K ﹤0.01% 1417
2025
Q4 		$53.4K Buy
1,297
+258
+25% +$10K ﹤0.01% 1777
2025
Q3 		$40.9K Buy
1,039
+553
+114% +$14.1K ﹤0.01% 1832
2025
Q2 		$9.05K Buy
486
+102
+27% +$1.91K ﹤0.01% 2190
2025
Q1 		$6.97K Sell
384
-327
-46% -$7.21K ﹤0.01% 2001
2024
Q4 		$15.5K Buy
711
+633
+812% +$16.3K ﹤0.01% 1958
2024
Q3 		$2.14K Buy
+78
New +$2.17K ﹤0.01% 2155

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Sterling Capital Management's DNTH Position: Q2 2026 in Review

Sterling Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 85% in Q2 2026, selling an estimated $82K and leaving 166 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1980.

Sterling Capital Management first reported a position in DNTH in Q3 2024 and has held it in 8 quarters since. The position peaked at $92.7K in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Sterling Capital Management held 166 shares of Dianthus Therapeutics worth $16.2K as of Q2 2026.
  • Sterling Capital Management sold 939 Dianthus Therapeutics shares in Q2 2026, an estimated $82K.
  • Dianthus Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1980 holding.
  • Sterling Capital Management first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Dianthus Therapeutics position peaked at $92.7K in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.